Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 235

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)

de Azambuja, Evandro, Procter, Marion J., van Veldhuisen, Dirk J., Agbor-Tarh, Dominique, Metzger-Filho, Otto, Steinseifer, Jutta, Untch, Michael, Smith, Ian E., Gianni, Luca, Baselga, Jose, Jackisch, Christian, Cameron, David A., Bell, Richard, Leyland-Jones, Brian, Dowsett, Mitch, Gelber, Richard D., Piccart-Gebhart, Martine J., Suter, Thomas M. · 2014 · Journal of Clinical Oncology

Abstract

Purpose: To document the rate and outcome of trastuzumab-associated cardiac dysfunction in patients following 1 or 2 years of adjuvant therapy. Patients and Methods: The Herceptin Adjuvant (HERA) trial is a three-arm, randomized trial comparing 2 years or 1 year of trastuzumab with observation in 5,102 patients with human epidermal growth factor receptor 2 (HER2) –positive early-stage breast cancer. Cardiac function was closely monitored. Eligible patients had left ventricular ejection fraction (LVEF) ≥ 55% at study entry following neoadjuvant chemotherapy with or without radiotherapy. This 8-year median follow-up analysis considered patients randomly assigned to 2 years or 1 year of trastuzumab or observation. Results: The as-treated safety population for 2 years of trastuzumab (n = 1,673), 1 year of trastuzumab (n = 1,682), and observation (n = 1,744) is reported. Cardiac adverse events leading to discontinuation of trastuzumab occurred in 9.4% of patients in the 2-year arm and 5.2% of patients in the 1-year arm. Cardiac death, severe congestive heart failure (CHF), and confirmed significant LVEF decrease remained low in all three arms. The incidence of severe CHF (0.8%, 0.8%, and 0.0%, respectively) and confirmed significant LVEF decrease (7.2%, 4.1%, and 0.9%, respectively) was significantly higher in the 2-year and 1-year trastuzumab arms compared with the observation arm. Severe CHF was the same for 2-year and 1-year trastuzumab. Of patients with confirmed LVEF decrease receiving 2-year trastuzumab, 87.5% reached acute recovery. Of patients with confirmed LVEF decrease receiving 1-year trastuzumab, 81.2% reached acute recovery. Conclusion: Long-term assessment at 8-year median follow-up confirms the low incidence of cardiac events for trastuzumab given sequentially after chemotherapy and radiotherapy, and cardiac events were reversible in the vast majority of patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2013.53.9288

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 235

Metadata

Authors
de Azambuja, E., Procter, M. J., van Veldhuisen, D. J., Agbor-Tarh, D., Metzger-Filho, O., Steinseifer, J., Untch, M., Smith, I. E., Gianni, L., Baselga, J., Jackisch, C., Cameron, D. A., Bell, R., Leyland-Jones, B., Dowsett, M., Gelber, R. D., Piccart-Gebhart, M. J., & Suter, T. M.
Venue
Journal of Clinical Oncology
Published
2014-07-10
Volume
32
Issue
20
Pages
2159-2165
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2090295140
Cited by
235
References
2
FWCI
21.06
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01). https://app.cochat.ai/papers/10.1200/jco.2013.53.9288
The paper
de Azambuja, E., Procter, M. J., van Veldhuisen, D. J., Agbor-Tarh, D., Metzger-Filho, O., Steinseifer, J., Untch, M., Smith, I. E., Gianni, L., Baselga, J., Jackisch, C., Cameron, D. A., Bell, R., Leyland-Jones, B., Dowsett, M., Gelber, R. D., Piccart-Gebhart, M. J., & Suter, T. M. (2014). Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2013.53.9288

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.